Stocktoria

Prestige Consumer Healthcare Inc. PBH

NYSE · stock · Pharmaceutical Preparations · website · IPO 2005-02-10

Prestige Consumer Healthcare Inc. (PBH) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2026 revenue was $1.1B at a 17.5% net margin.

Chart by TradingView
68/100
Stocktoria Quality Score · grade B
5/9
Piotroski F — financial health
4.04
Altman Z″ — distress risk · safe
Dividend yield · no dividend
-2.52
Beneish M-score — earnings quality · low

Quality score trend · recomputed for each fiscal year

Piotroski F /9
3 6 6 8 8 6 6 8 7 5 2017201820192020202120222023202420252026
Altman Z″
1.25 1.82 1.62 2.27 2.51 2.74 2.30 3.57 4.04 4.04 2017201820192020202120222023202420252026

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$52.27 as of 2026-08-01 · -23.2% 1y
$47.27$69.3052-wk

Beneish M-score: -2.52 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.

Market cap USD$2.3B
P / E12.3×
Net margin 5y avg13.3%
Return on equity 5y avg8.3%
Beta0.35
Employees890

Analyst price target

$66.80 +27.8% vs last
· 5 analysts
target range $50.00 – $75.00 · median $70.00
5 buy · 2 hold
Recent analyst actions
DateFirmRating
2026-05-15Canaccord GenuityBuy (main)
2026-05-14OppenheimerPerform (down)
2026-05-07OppenheimerOutperform (main)
2026-02-02JefferiesHold (main)
2025-11-07Canaccord GenuityBuy (main)
2025-10-27JefferiesHold (main)

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Smart money · insiders, last 12 months

Insiders net sold -$101,303 on the open market · 3 trades

Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.

Revenue trend · last 10y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 63%
Net marginstronger than 91%
Return on equitystronger than 74%
Revenue growthstronger than 23%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 5/9 tests passed

Altman Z″ components · safe zone

ComponentValue
Working capital / assets0.089
Retained earnings / assets0.5
EBIT / assets0.089
Equity / liabilities1.175

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
PBHPrestige Consumer Healthcare Inc.5/94.0412.3-4.3%
ACADACADIA PHARMACEUTICALS INC4/93.7911.1+11.9%
MDGLMADRIGAL PHARMACEUTICALS, INC.3/9-1.18+432.1%
IONSIONIS PHARMACEUTICALS INC3/91.12+33.8%
NSRXNasus Pharma Ltd3/9-13.82
INDVIndivior Pharmaceuticals, Inc.4/9-0.724.3+4.3%
ANIPANI PHARMACEUTICALS INC6/93.2624.5+43.8%

All Manufacturing companies →

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

FAQ

Is PBH financially healthy?

Prestige Consumer Healthcare Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.

Does PBH pay a dividend?

No, Prestige Consumer Healthcare Inc. does not currently pay a dividend.

How profitable is PBH?

In FY2026, Prestige Consumer Healthcare Inc. had a net margin of 17.5% and a return on equity of 10.1%.

Is PBH overvalued or undervalued?

Prestige Consumer Healthcare Inc. trades at about 13.4× trailing earnings — below its 10-year norm (10-year range 4.6×–44.2×, median 17.2×). Stocktoria reports the data, not buy/sell advice.

What is the analyst price target for PBH?

The average Wall-Street price target for Prestige Consumer Healthcare Inc. is $66.80, about 27.8% above the recent price, from 5 analysts.

Is PBH a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on Prestige Consumer Healthcare Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 12.3×. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.